Observational studyMedicine2026
Predicting mucosal healing in patients with ulcerative colitis in clinical remission using biomarkers: A single-center prospective pilot study.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Treating ulcerative colitis (UC) requires mucosal healing (MH); however, clinical remission does not always involve MH. Fecal calprotectin (FC) is a useful marker to determine MH. Leucine-rich alpha-2 glycoprotein (LRG) and prostaglandin E-major urinary metabolite (PGE-MUM) have similar performance to FC and may also predict MH. No previous studies have provided a detailed comparative analysis of LRG, PGE-MUM, and FC. Herein, we investigated their associations with endoscopic activity and their potentials as predictors of MH. This single-center, prospective, observational study included patients with ulcerative colitis in clinical remission for >3 months (partial Mayo score ≤ 2) who were to undergo colonoscopy between July 2023 and June 2024. Endoscopic remission (ER) was defined as Mayo endoscopic score of 0, while histological remission (HR) was based on the Geboes score. Overall, 46 patients were enrolled, and all underwent colonoscopy; 20 (43%) had ER, and 9 (20%) had HR. The median LRG, PGE-MUM, and FC levels were significantly higher in patients without ER than in those who achieved ER (P < .05). The areas under the receiver operating characteristic curves of LRG, PGE-MUM, and FC for determining ER were 0.686 (95% confidence interval [CI]: 0.530-0.845), 0.695 (95% CI: 0.552-0.872), and 0.788 (95% CI: 0.658-0.919), respectively. The optimal cutoff value obtained from the receiver operating characteristic curve, LRG, PGE-MUM, and FC values for determining ER were 14.2 µg/mL, 30.6 μg/gCr, and 143 mg/kg, respectively. The areas under the receiver operating characteristic curves for LRG + FC and PGE-MUM + FC to determine ER were 0.800 (95% CI: 0.672-0.928) and 0.865 (95% CI: 0.764-0.966), respectively. LRG and PGE-MUM are potential biomarkers for determining ER in clinical remission. Combining LRG and PGE-MUM assessments with FC may improve the accuracy of confirming ER in ulcerative colitis, even during the remission phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.